Vol 21, No 2 (2018)
Clinical vignette
Published online: 2018-06-11

open access

Page views 2662
Article views/downloads 1058
Get Citation

Connect on Social Media

Connect on Social Media

Simultaneous breast cancer and DLBCL lymphoma — role of PET/CT examination with 18F-FDG and 18F-FES

Łukasz Hołody1, Jolanta Kunikowska2, Janusz Braziewicz3
Pubmed: 29956818
Nucl. Med. Rev 2018;21(2):113-114.

Abstract

Breast cancer is the most common cancer in women in the western world.

The estrogen receptor (ER) is expressed in two thirds of newly diagnosed breast cancers, so hormonal treatment is performed only in the receptor positive patients. The most successful ER imaging radiopharmaceutical in PET techniques is 16α-[18F]-flouro-17β-estradiol (18F-FES).

The diffuse large B cell lymphoma (DLBCL) is one of the most common NHL, however, non-Hodgkin lymphoma constitutes only 4% of all primary cancers in women. The typical staging of disease is done using 18-fluorodeoksyglukose (18F-FDG) PET/CT.

Article available in PDF format

View PDF Download PDF file